Isthmus Partners LLC Takes Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Isthmus Partners LLC bought a new stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) during the third quarter, Holdings Channel reports. The institutional investor bought 3,202 shares of the specialty pharmaceutical company’s stock, valued at approximately $357,000.

A number of other large investors also recently modified their holdings of JAZZ. California State Teachers Retirement System lifted its holdings in shares of Jazz Pharmaceuticals by 3.2% in the first quarter. California State Teachers Retirement System now owns 102,353 shares of the specialty pharmaceutical company’s stock valued at $12,325,000 after purchasing an additional 3,172 shares in the last quarter. Tidal Investments LLC lifted its holdings in shares of Jazz Pharmaceuticals by 179.4% in the first quarter. Tidal Investments LLC now owns 16,655 shares of the specialty pharmaceutical company’s stock valued at $2,006,000 after purchasing an additional 10,693 shares in the last quarter. DekaBank Deutsche Girozentrale lifted its holdings in Jazz Pharmaceuticals by 26.0% during the first quarter. DekaBank Deutsche Girozentrale now owns 115,308 shares of the specialty pharmaceutical company’s stock worth $13,938,000 after acquiring an additional 23,768 shares during the period. GAMMA Investing LLC lifted its holdings in Jazz Pharmaceuticals by 65.5% during the second quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company’s stock worth $31,000 after acquiring an additional 116 shares during the period. Finally, Versant Capital Management Inc lifted its holdings in Jazz Pharmaceuticals by 13,450.0% during the second quarter. Versant Capital Management Inc now owns 271 shares of the specialty pharmaceutical company’s stock worth $29,000 after acquiring an additional 269 shares during the period. Institutional investors own 89.14% of the company’s stock.

Insider Activity

In related news, CEO Bruce C. Cozadd sold 1,000 shares of the business’s stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $110.84, for a total transaction of $110,840.00. Following the completion of the transaction, the chief executive officer now directly owns 428,976 shares in the company, valued at $47,547,699.84. The trade was a 0.23 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Mary Elizabeth Henderson sold 1,410 shares of the business’s stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $108.30, for a total value of $152,703.00. Following the transaction, the senior vice president now owns 14,531 shares of the company’s stock, valued at approximately $1,573,707.30. The trade was a 8.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 6,110 shares of company stock worth $720,160. 4.20% of the stock is owned by corporate insiders.

Jazz Pharmaceuticals Price Performance

Shares of NASDAQ JAZZ opened at $121.59 on Friday. The stock has a market cap of $7.35 billion, a PE ratio of 17.13, a price-to-earnings-growth ratio of 1.03 and a beta of 0.57. Jazz Pharmaceuticals plc has a fifty-two week low of $99.06 and a fifty-two week high of $134.17. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. The stock has a fifty day moving average of $114.87 and a 200-day moving average of $111.12.

Wall Street Analyst Weigh In

A number of analysts recently commented on the company. Cantor Fitzgerald reiterated an “overweight” rating and set a $140.00 price target on shares of Jazz Pharmaceuticals in a report on Monday, September 9th. HC Wainwright reiterated a “buy” rating and set a $200.00 price target on shares of Jazz Pharmaceuticals in a report on Friday, November 22nd. Robert W. Baird lifted their price target on Jazz Pharmaceuticals from $154.00 to $162.00 and gave the stock an “outperform” rating in a report on Monday, November 18th. TD Cowen dropped their price target on Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating on the stock in a report on Thursday, November 7th. Finally, JPMorgan Chase & Co. raised their target price on Jazz Pharmaceuticals from $190.00 to $202.00 and gave the stock an “overweight” rating in a research report on Monday, August 19th. Three equities research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $175.33.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.